CCND1 expression
|
Diffuse Large B Cell Lymphoma
|
CCND1 expression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
AP2M1 overexpression
|
Diffuse Large B Cell Lymphoma
|
AP2M1 overexpression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 positive + LGALS3 expression
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive + LGALS3 expression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab + polatuzumab vedotin Sensitive: A1 - Approval
|
rituximab + polatuzumab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lenalidomide + tafasitamab Sensitive: A1 - Approval
|
lenalidomide + tafasitamab Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
loncastuximab tesirine Sensitive: A1 - Approval
|
loncastuximab tesirine Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
selinexor Sensitive: A1 - Approval
|
selinexor Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
rituximab / hyaluronidase Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
polatuzumab vedotin Sensitive: A2 - Guideline
|
polatuzumab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
TNFRSF8 positive
|
Diffuse Large B Cell Lymphoma
|
TNFRSF8 positive
|
Diffuse Large B Cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
MINE Sensitive: A2 - Guideline
|
MINE Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-GemOx Sensitive: A2 - Guideline
|
R-GemOx Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
GemOx Sensitive: A2 - Guideline
|
GemOx Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
ESHAP Sensitive: A2 - Guideline
|
ESHAP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
ICE Sensitive: A2 - Guideline
|
ICE Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
RICE Sensitive: A2 - Guideline
|
RICE Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
carboplatin + rituximab + gemcitabine + dexamethasone Sensitive: A2 - Guideline
|
carboplatin + rituximab + gemcitabine + dexamethasone Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline
|
carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
GDP Sensitive: A2 - Guideline
|
GDP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
RGDP Sensitive: A2 - Guideline
|
RGDP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
DHAX Sensitive: A2 - Guideline
|
DHAX Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
DHAP Sensitive: A2 - Guideline
|
DHAP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-DHAP Sensitive: A2 - Guideline
|
R-DHAP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
EPOCH-R Sensitive: A2 - Guideline
|
EPOCH-R Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
CEOP Sensitive: A2 - Guideline
|
CEOP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
CEPP Sensitive: A2 - Guideline
|
CEPP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-ESHAP Sensitive: A2 - Guideline
|
R-ESHAP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-GCVP Sensitive: A2 - Guideline
|
R-GCVP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-CEOP Sensitive: A2 - Guideline
|
R-CEOP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-CEPP Sensitive: A2 - Guideline
|
R-CEPP Sensitive: A2 - Guideline
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
R-CDOP Sensitive: A2 - Guideline
|
R-CDOP Sensitive: A2 - Guideline
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
MYC overexpression + BCL2 overexpression
|
Diffuse Large B Cell Lymphoma
|
MYC overexpression + BCL2 overexpression
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
LDH elevation
|
Diffuse Large B Cell Lymphoma
|
LDH elevation
|
Diffuse Large B Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
ALLO-501A Sensitive: B - Late Trials
|
ALLO-501A Sensitive: B - Late Trials
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
EZM0414 Sensitive: B - Late Trials
|
EZM0414 Sensitive: B - Late Trials
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
FT516 Sensitive: B - Late Trials
|
FT516 Sensitive: B - Late Trials
|
EZH2 mutation
|
Diffuse Large B Cell Lymphoma
|
EZH2 mutation
|
Diffuse Large B Cell Lymphoma
|
tazemetostat Sensitive: C1 - Off-label
|
tazemetostat Sensitive: C1 - Off-label
|
BCL2 expression
|
Diffuse Large B Cell Lymphoma
|
BCL2 expression
|
Diffuse Large B Cell Lymphoma
|
venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria
|
venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
MYC expression
|
Diffuse Large B Cell Lymphoma
|
MYC expression
|
Diffuse Large B Cell Lymphoma
|
RG6146 Sensitive: C2 – Inclusion Criteria
|
RG6146 Sensitive: C2 – Inclusion Criteria
|
BIRC5 expression
|
Diffuse Large B Cell Lymphoma
|
BIRC5 expression
|
Diffuse Large B Cell Lymphoma
|
pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
GEN3013 Sensitive: C2 – Inclusion Criteria
|
GEN3013 Sensitive: C2 – Inclusion Criteria
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
|
BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: C2 – Inclusion Criteria
|
rituximab Sensitive: C2 – Inclusion Criteria
|
NOTCH1 mutation
|
Diffuse Large B Cell Lymphoma
|
NOTCH1 mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: C2 – Inclusion Criteria
|
rituximab Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
Diffuse Large B Cell Lymphoma
|
TP53 mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab Resistant: C2 – Inclusion Criteria
|
rituximab Resistant: C2 – Inclusion Criteria
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
MYC overexpression
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Resistant: C3 – Early Trials
|
tisagenlecleucel-T Resistant: C3 – Early Trials
|
MYC negative
|
Diffuse Large B Cell Lymphoma
|
MYC negative
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
MYC positive
|
Diffuse Large B Cell Lymphoma
|
MYC positive
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
MAD2L2 overexpression
|
Diffuse Large B Cell Lymphoma
|
MAD2L2 overexpression
|
Diffuse Large B Cell Lymphoma
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
CRTAM overexpression
|
Diffuse Large B Cell Lymphoma
|
CRTAM overexpression
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
BTLA overexpression
|
Diffuse Large B Cell Lymphoma
|
BTLA overexpression
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
LEF1 overexpression
|
Diffuse Large B Cell Lymphoma
|
LEF1 overexpression
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
KLHL14 mutation
|
Diffuse Large B Cell Lymphoma
|
KLHL14 mutation
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
LRP1B mutation
|
Diffuse Large B Cell Lymphoma
|
LRP1B mutation
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
methotrexate Sensitive: C3 – Early Trials
|
methotrexate Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
cytarabine + methotrexate Resistant: C3 – Early Trials
|
cytarabine + methotrexate Resistant: C3 – Early Trials
|
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
|
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
|
methotrexate Resistant: C3 – Early Trials
|
methotrexate Resistant: C3 – Early Trials
|
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
|
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
|
cytarabine + methotrexate Resistant: C3 – Early Trials
|
cytarabine + methotrexate Resistant: C3 – Early Trials
|
BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
EPOCH-R Sensitive: C3 – Early Trials
|
EPOCH-R Sensitive: C3 – Early Trials
|
LDH elevation
|
Diffuse Large B Cell Lymphoma
|
LDH elevation
|
Diffuse Large B Cell Lymphoma
|
ViPOR Sensitive: C3 – Early Trials
|
ViPOR Sensitive: C3 – Early Trials
|
BCL6 translocation
|
Diffuse Large B Cell Lymphoma
|
BCL6 translocation
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: C3 – Early Trials
|
R-CHOP Sensitive: C3 – Early Trials
|
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
|
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
|
R-CHOP Resistant: C3 – Early Trials
|
MYC translocation + BCL2 translocation
|
Diffuse Large B Cell Lymphoma
|
MYC translocation + BCL2 translocation
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: C3 – Early Trials
|
R-CHOP Sensitive: C3 – Early Trials
|
MYC translocation + BCL6 translocation
|
Diffuse Large B Cell Lymphoma
|
MYC translocation + BCL6 translocation
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: C3 – Early Trials
|
R-CHOP Sensitive: C3 – Early Trials
|
MYC positive + BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
MYC positive + BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: C3 – Early Trials
|
axicabtagene ciloleucel Sensitive: C3 – Early Trials
|
MYC positive + BCL2 positive + BCL6 positive
|
Diffuse Large B Cell Lymphoma
|
MYC positive + BCL2 positive + BCL6 positive
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: C3 – Early Trials
|
axicabtagene ciloleucel Sensitive: C3 – Early Trials
|
BCL2 amplification
|
Diffuse Large B Cell Lymphoma
|
BCL2 amplification
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
|
R-CHOP Resistant: C3 – Early Trials
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|